Purpose. The efficacy, safety, pharmacology, pharmacokinetics, drug–drug interactions, and administration of alvimopan for postoperative ileus are reviewed. Summary. Alvimopan is a selective µ-opioid ...

EXTON, Pa.--(BUSINESS WIRE)-- Adolor Corporation (NasdaqGM: ADLR) today announced that the results of a Medication Use Evaluation (MUE) conducted by clinical pharmacists and surgeons at the Moses Cone ...

ORLANDO -- Alvimopan, an oral peripherally acting mu-opioid receptor antagonist, decreased postoperative ileus after major abdominal surgery among patients with inflammatory bowel disease (IBD), ...

EXTON, Pa. & PHILADELPHIA -- Feb 8, 2008 - Adolor Corporation and GlaxoSmithKline today announced that the U.S. Food and Drug Administration (FDA) has informed Adolor that the Prescription Drug User ...

Discover comprehensive details about Alvimopan Capsules, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

Adolor Corporation has received two additional patents related to alvimopan from the United States Patent and Trademark Office. The first patent is directed to the use of alvimopan in the treatment ...

Review the side-effects of Alvimopan Capsules as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority ...

Alvimopan Capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis. Hikma is ...

Postoperative ileus is a common complication and can be associated with prolonged hospital stay. Alvimopan, a µ-opioid receptor antagonist, has been shown to reduce the duration of postoperative ileus ...

New study data show that alvimopan—a μ-opioid antagonist that competitively binds to, but doesn't activate, the μ-opioid receptor in the gastrointestinal tract—expedites gastrointestinal recovery and ...

Am J Health Syst Pharm. 2009;66(14):1267-1277. Concentrations of both alvimopan and its metabolite are 1.9- and 1.4-fold greater in surgical patients, respectively, relative to healthy volunteers, ...